In order to search for effective and low toxicity anti-tumor angiogenesis drugs, jiangsu
hengrui pharmaceutical co., ltd. developed the high-efficiency VEGFR2 tyrosine kinase
inhibitor apatinib. This drug is mainly used to treat malignant tumors by inhibiting VEGFR2
to play an anti-angiogenic role. Both in vivo and in vitro experiments have shown that
apatinib has good tumor growth inhibition activity for lung cancer. This study aims to
further confirm the effectiveness and safety of apatinib third-line treatment for patients
with advanced lung squamous cell carcinoma.